⚡ Flash Summary
Sitara Peroxide Limited (SPL) reported its financial results for the first quarter ended September 30, 2024. Due to the complete closure of the plant for balancing, modernization, and replacement (BMR), the company experienced zero sales during the quarter, compared to PKR 15.868 million in the same period last year. Despite no revenue, the company managed to reduce its loss after tax to PKR 70.754 million from PKR 78.833 million in the corresponding period of the previous year, primarily through cost reduction and lower finance costs. The company awaits early BMR completion for viable operations.
📌 Key Takeaways
- 📉 Sales plummeted to zero due to plant closure for BMR.
- ❌ No revenue generated in Q1 2024 vs. PKR 15.868 million in Q1 2023.
- 💰 Cost of sales decreased to PKR 53.828 million from PKR 63.637 million.
- ⚠️ Gross loss stood at PKR 53.828 million.
- ➡️ Loss before tax improved slightly to PKR 81.453 million from PKR 78.595 million.
- ✅ Loss after tax reduced to PKR 70.754 million from PKR 78.833 million.
- 📉 Loss per share reduced to PKR 1.28 from PKR 1.43.
- ✔️ Depreciation decreased slightly from PKR 43.179 million to PKR 42.509 million.
- 📉 Finance costs decreased due to loan repayments.
- 👍 All expenses reduced by management.
- 🛠️ BMR is underway for viable operation.
- 🏦 Cash and bank balances increased to PKR 36.233 million from PKR 11.381 million at the beginning of the period.
- 📉 Revenue reserve shows accumulated loss of PKR 768.456 million.
- 👍 Net cash generated from operating activities is PKR 24.851 million compared to negative PKR 8.973 million last year.
🎯 Investment Thesis
Given the plant closure and ongoing BMR, a HOLD recommendation is appropriate. The company’s future prospects depend heavily on the successful completion of BMR and the resumption of profitable operations. Any potential BUY recommendation would depend on tangible progress on BMR and a clear timeline for resuming operations. Price target is speculative until operations resume.
Disclaimer: AI-generated analysis. Not financial advice.